Compare Abeona Therapeutics Inc (ABEO) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs PepsiCo, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while PepsiCo, Inc. trades at $143.86 (market cap $198.15B). The key difference: PepsiCo, Inc. is far larger — about 530.8× Abeona Therapeutics Inc's market cap, and PepsiCo, Inc. pays a 4.08% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | PEP | |
|---|---|---|
Market Cap | $373.32M | $198.15B |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $170.44 |
52-Week Low | $4.17 | $133.81 |
Enterprise Value | $228.22M | $240.05B |
Dividend Yield | — | 4.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
PepsiCo (PEP) trades at $143.66, up 0.26% on the day, with a bullish technical signal and strong profitability metrics including a 54.06% gross margin and 43.92% ROE. Recent earnings have consistently beaten estimates, and the company maintains a solid cash flow profile. News highlights a strategic price reduction on snacks to address consumer pushback and a focus on North American recovery.
The outlook is positive with a consensus price target of $161.73, implying potential upside. Key risks include competitive pressures and sensitivity to consumer spending. Analyst sentiment is mixed but leans bullish, supported by institutional accumulation and a sustainable dividend yield near 4%.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
